Investing in psychedelics has gained traction in recent years with states such as California and Colorado decriminalising psilocybin ("magic truffles"). In November 2020 Oregon has both decriminalised and legalised psilocybin for therapeutic use.
With the increase in mental health concerns caused by lockdowns and the opioid crisis in the US, investing in psychedelics could be huge for pharmaceutical companies.
There are still many regulatory barriers. However, the FDA's approval rate has increased in recent years due to new regulatory frameworks, new technologies and high R&D spending.
High volatility is expected with the below stocks, play it safe!